31st Annual Credit Suisse Healthcare Conference Read more about 31st Annual Credit Suisse Healthcare Conference
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference Read more about bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Read more about bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall Read more about Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
bluebird bio Announces September Investor Events Read more about bluebird bio Announces September Investor Events
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress